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resumo 
 
 
O presente estudo foi levado a cabo com o intuito de identificar possíveis 
proteínas que interajam com PrPC que possam fornecer novos conhecimentos 
sobre as suas funções fisiológicas assim como no papel patológico. O 
presente estudo incidiu na investigação dos níveis das proteínas endossomais 
Rab7a e Rab9 em amostras do córtex frontal e cerebelo de pacientes 
diagnosticados com sCJD-MM1 e sCJD-VV2. Observamos um aumento 
significativo dos níveis intracelulares do Rab7a em pacientes diagnosticados 
com sCJD-MM1 e sCJD-VV2 quando comparadas com amostras de pacientes 
na mesma faixa etária sem a doença (controlo). As interações entre PrPC e as 
proteínas Rab7a e Rab9 foram posteriormente estudadas com o auxílio à 
microscopia confocal. Os resultados da imunofluorescência sugeriram 
potenciais interações entre as proteínas Rab7a com o PrPC. O siRNA-Rab7 foi 
usado para diminuir a expressão da proteína Rab7a (“Knockdown”) na cultura 
primária de células do córtex de ratos saudáveis. Na cultura de células do 
córtex tratadas com o siRNA-Rab7, foi observado um emparelhamento da via 
endocítica. Seguidamente investigamos possíveis interações da proteína Tau 
com a proteína Rab7a, recorrendo ao western blot e a microscopia confocal. 
Culturas de células do córtex de ratos saudáveis foram tratadas com siRNA-
Tau, siRNA-Rab7a e siRNA. Os resultados da imunofluorescência das 
diferentes culturas celulares sugeriram uma potencial interação entre as 
proteínas Tau e Rab7a. Nas linhas celulares tratadas com siRNA-Tau os níveis 
intracelulares das proteínas Rab7a e Rab9 aumentaram significativamente, 
assim como, foi também observada a alteração da sua localização. Nas 
células tratadas com siRNA-Rab7a observamos uma diminuição da 
acumulação da proteína Tau na região citosólica. Em conclusão, este trabalho 
pode ajudar a perceber e a caracterizar a progressão da doença nos subtipos 
específicos, no caso de sCJD. Contudo, este trabalho poderá ser também um 
passo à frente para o desenvolvimento de novas estratégias terapêuticas para 
os subtipos sCJD-MM1 e sCJD-VV2.    
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abstract 
 
The present study was undertaken to identify proteins interacting with PrPC that 
could provide new insights into its physiological functions and pathological role. 
We performed a target search for lysosomal network protein, Rab7a and Rab9, 
in frontal cortex and cerebellum of human brain from patients with sCJD-MM1 
and sCJD-VV2. The intracellular level of Rab7a was increased significantly, 
when compared with healthy age-matched control. Interactions of PrPC and 
Rab7a/Rab9 were further investigated by using confocal laser scanning 
microscopy. Immunofluorescence results suggested potential interactions of 
Rab7a and PrPC. siRNA against the Rab7a gene was used to knockdown the 
expression of Rab7a protein in primary cell culture of cortical neurons from wild 
type mice. This depleted Rab7a resulted an impairment of PrPC trafficking 
leading to an accumulation of PrPC in the endocytosis pathway. Furthermore, 
interactions of Tau and Rab7a were investigated by using western blot analysis 
and confocal laser scanning microscopy. Cell cultures of cortex of wildtype 
mice were treated with siRNA-Tau, siRNA-Rab7 and control siRNA followed by 
immunofluorescence. The results of immunofluorescence suggested potential 
interaction of Tau and Rab7a. Cells lines treated with siRNA-Tau, the 
intracellular levels of Rab7a and Rab9 significantly increases and their 
localization is also modified. When we transfected this cells lines with siRNA-
rab7a the accumulation of Tau decreases in cytosolic region and their 
localization was also modified when compared with control cells. In conclusion, 
this study may help to understand and characterize the subtype specific 
disease progression in CJD cases. Furthermore, it could be a step ahead to 
development of new treatment strategies for diseases subtype specific manner. 
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I Introduction 
1 Cellular prion protein (PrPC)  
The cellular form of the prion protein (PrPC) is a glycosyl-phosphatidyl-
inositol (GPI)-anchored glycoprotein, highly expressed in the neurons of the brain 
and spinal cord region (Stahl et al. 1987). However, the physiological function of 
PrPC is still not clear, in recent years, some putative functional aspects were 
attributed to PrPC,  synaptic regulatory response (as a receptor or receptor-related 
in GABAA-ergic inhibitory synapses) (Puoti et al. 2012), sleep and circadian 
rhythms regulator, inhibitory regulation of N-methyl-D-aspartate (NMDA) receptors, 
interaction with stress inducible protein 1 (STI1), regulation of cell differentiation 
and apoptosis, maintenance of peripheral nerve myelin, role in neuronal growth 
and survival (protection against bax-mediated cell death); signal transduction 
(caveolin1-dependent coupling to tyrosine kinase Fyn); signaling receptor (binding 
to neural cell adhesion molecule); oxidative stress, copper binding (cooper serving 
as a cofactor for an undetermined PrPc enzyme activity) (Lorca et al. 2011; Martins 
et al. 2010), receptor for amyloid beta in Alzheimer’s disease and possibly for 
other amyloids (Laurén et al. 2009; Resenberger et al. 2011) and it is known that 
the conformal change of PrPc can cause serious neurodegenerative diseases 
(Nicolas et al. 2009). 
The PrPc is synthesized in the endoplasmic reticulum (ER), processed in 
golgi apparatus and then transferred to the plasmatic membrane in full length 
form. During its synthesis the cellular prion can take various forms in the ER. The 
PrPc can be found at least in two transmembrane topologies (Hegde & Lingappa 
1999): 
 
1. ctmPrP = The ctmPrP form is when the c-terminal of PrPc is in the ER 
lumen, 
 
2. NtmPrP = The NtmPrP form is when the N-terminius of PrPc is in the ER 
lumen (Figure 1). 
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Figure 1. Putative mechanism for generating different topological forms: The PrPc is 
translocated to the endoplasmic reticulum (ER) by ribosomes. The nascent protein chain containing 
a transmembrane (TM) domain (shaded rectangle) can have different orientations into the ER 
membrane. This process depends on a particular translocation accessory factor (TrAF #1) that 
might shield the hydrophobic TM domain from being recognized by the translocon, allowing it to be 
translocated into the ER lumen leading to cyPrP form. If TM domain is recognized by translocation 
machinery ((b) or (c)), another translocation accessory factor (TrAF #2) interacts with nascent 
chain leading to NtmPrP form (b) or if there is no interaction of the translocation accessory factor 
(TrAF #2) with, the nascent chain, the least energetically demanding orientation, is favoured the 
ctmPrP form (c). The final topology resulting from each of these possibilities is shown at the top of 
the diagram (Take from Hegde e Lingappa, 1999). 
 
The transportation of PrPc leads to unglycosylated and glycosylation (mono- 
and di- glycosylated) forms formed in RE and it is transported to the golgi 
apparatus for further modifications (Figure 2). Therefore the cellular prion is 
transported to the cellular membrane under its mature form, PrPc (Harris 2003). 
The PrPc can still be found in the cytosol, cyPrP. The cyPrP can be the result of 
controlled mechanisms of ER. When the protein is misfolded or under ER stress 
conditions, proteins undergo retrograde transport to the cytosol, become 
polyubiquitinated, and are degraded by the proteasome through a process called 
ER-associated degradation, ERAD (Lin et al. 2013). 
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Figure 2. Primary structure of PrPc including posttranslational modifications: A secretory 
signal peptide resides at the extreme NH2 terminus. CC1 and CC2 define the charged clusters. OR 
indicates the octapeptide repeat, and four are present. HC defines the hydrophobic core. MA 
denotes the membrane anchor region. S-S indicates the single disulfide bridge, and the 
glycosylation sites are designated as CHO. The numbers describe the position of the respective 
amino acids (Take from Aguzzi e Calella, 2009). 
 
1.1 Structure of cellular prion and prion disease 
The structure of PrPc is composed of three regions; alpha-helix (~ 40% of 
protein) separated by loop/turn regions and by two small regions of beta-sheet (~ 
3% of protein). This conformation of PrPc is sensitive to proteolysis, PrP-sen. 
However, when PrPc undergoes structural changes, it leads to the increase of 
beta-sheets ~ 40%, and PrPc becomes misfolded and resistant to proteases 
attack, PrP-res (Prusiner 2004; Novakofski et al. 2005).  
The conversion of PrP-sen to PrP-res can occur when PrP-res binds to PrPc 
or when the PrP-sen conformation is altered into PrP-res by a poorly understood 
pathway (Figure 3). Its conversion on the cell surface leads to PrP-res 
accumulation extracellularly, and  along endocytic pathway leads to accumulation 
of PrP-res in the lysosome (Moore et al. 2009; Lee et al. 2013). The accumulation 
of PrP-res in the lysosomes leads eventually to lysosome´s burst and the release 
of all lysosomal enzymes together with the PrP-res in the cytoplasm,  leading to 
cells apoptosis (Araújo 2013). 
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Figure 3. Structure of PrPc and PrPSc: Normal and disease-causing prions structures (Take from 
Lee et al., 2013). 
 
1.2 PrP-res form and prion diseases 
PrP-res accumulates intra and/or extracellularly leading to the 
neurodegenerative diseases called transmissible spongiform encephalopathies 
(TSEs),also called prion diseases. The aggregates of PrP-res yield neurological 
dysfunctions and cells death. The brain lost neurons and with advancing disease 
the brain looks like a sponge form leads to death in humans and other mammals 
(Belay 1999). In mammals, the TSE occurs as scrapie disease ( sheep), 
transmissible mink encephalopathy (mink), chronic wasting disease (deer), bovine 
spongiform encephalopathy (cattle) and feline spongiform encephalopathy (cats). 
The most common prion disease present in humans is Creutzfeldt-Jakob disease 
(Lee et al. 2013; Moore et al. 2009). 
 
Table 1. Transmissible spongiform encephalopathies (TSEs) in humans and animals 
(Liemann & Glockshuber 1998; Puoti et al. 2012). 
 
Disease name Animal species Etiology 
Scrapie Sheep Infection 
Transmissible mink 
encephalopathy 
Mink Infection 
Chronic wasting disease Deer Infection 
Bovine spongiform 
encephalopathy 
Cows Infection 
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Feline spongiform 
encephalopathy 
Cats Infection 
Bovine spongiform 
encephalopathies  
Cattle Infection 
Creutzfeldt-Jakab disease 
Iatrogenic 
Sporadic  
Inherited 
New variant 
Humans  
Infection 
Unknown 
Mutation in PrP gene 
Infection from bovine prion? 
Gerstmann-Stränssler-
Scheinker syndrome 
Humans  Mutation in PrP gene 
Fatal familial insomnia Humans Mutation in PrP gene 
 
2 Creutzfeldt-Jakob disease (CJD) 
The sporadic Creutzfeldt Jakob disease (sCJD) is the most common form of 
prion disease (85% to 95%) of all human prion disease (Ladogana et al. 2005; 
Masters et al. 1979). In sCJD, the source of contamination is unknown. The 
disease is not associated with any mutation in PRNP allele or by any exposure to 
Prion disease. However, studies have been documented that people with a 
medical history of psychosis, family history of CJD, history of multiple surgical 
procedures and residence for more than 10 years on a farm have a significant risk 
to develop sCJD (Villemeur 2013). 
The sCJD is the prion disease with the highest degree of phenotypic 
heterogeneity. This phenotype heterogeneity has been associated with 
polymorphisms of codon 129 of the prion protein gene (PRNP) and to the size of 
protease resistant core of the prion protein (PrPSc), ~21 KDa (type 1) and ~19KDa 
(type 2). The codon 129 of PRNP consists in an amino acid methionine (M) or 
valine (V) in each allele. The the resistant core of PrPSc patient genotype can be 
MM, MV or VV with type 1 or type 2 of and therefore, they have a different 
phenotype of prion disease (Figure 4) (Parchi, Capellari, et al. 1999). The sCJD is 
subdivided in 6 subtype, sCJD MM1, sCJD MM2, sCJD MV1, sCJD MV2, sCJD 
VV1 and sCJD VV2. And these subtypes were grouped in two groups, sCDJ 
cognitive type and sCDJ ataxic type. Each group and subtypes are characterized 
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by different clinical and histopathological features (Cali et al. 2009; Puoti et al. 
2012). 
 
 
Figure 4. Correlations between the PrP genotype, as determined by the MV polymorphism at 
codon 129, and PrPSc types 1 and 2: (A) Diagrammatic representation of each of the three 129 
genotypes (MM, MV, and VV) with their average relative prevalence in all subtypes of sCJD. (B) 
PrPSc type 1 is associated with the 129MM genotype in about 95% of cases, whereas MV and VV 
genotypes are associated with PrPSc type 2 in about 86% of cases. (C) Diagrammatic 
representation of PrPSc types 1 and 2; each consists of an amino-terminal region (N) of different 
sizes that is protease-sensitive and is digested down to amino acid (aa) 82 in type 1 and to amino 
acid 97 in type 2 (arrows). The different cleavage site is thought to be the result of the different 
conformation in PrPSc types 1 and 2. (D) Types 1 and 2 PrPSc have distinct electrophoretic 
mobilities because of the different size of their respective protease-resistant fragments (type 2 
being smaller than type 1) and are easily distinguished by their different migration on 
electrophoresis, especially after cleavage of the sugars by the enzyme peptide N glycosidase F 
(PNGase). (E) Both 129 genotype and PrPSc types are thought to act as determinants of the 
phenotypes of sporadic prion diseases that are commonly identified with letters and numbers to 
indicate the associated genotype and PrPSc type. PrPSc=scrapie prion protein. M=methionine. 
V=valine. sCJD=sporadic Creutzfeld-Jakob disease. sFI=sporadic fatal insomnia (Take from Puoti 
et al., 2012). 
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2.1 sCJD cognitive type 
2.1.1 sCJD MM1 and sCJD MV1  
These  sCJD subtypes account for approximately between 60 to 70% of 
sCJD cases and are observed in individual with genotype MM or MV at codon 129 
of the PrP gene and carrie type 1 of PrPSc. However, approximately 95% of 
individuals in this subgroup belong to MM1 genotype in codon 129, while the 
individuals with genotype MV are rare (Gambetti et al. 2003). The MM1 and MV1 
genotype are clinical and histopathology indistinguishable, the difference between 
both is the 129 genotype. Therefore, the MM1 and MV1 belong to the same 
subgroup (Takada & Geschwind 2013; Puoti et al. 2012). The mean age onset of 
disease is around 66 years old and this subtype has a short duration of illness. 
When patients have severe signs of the disease in a few weeks enter vegetative 
state and die, the mean duration of the disease is 4 month after onset (Parchi, 
Giese, et al. 1999; Parchi et al. 2009).  
The phenotype associated with subtype MM1/MV1 is characterized by 
rapidly progressive cognitive decline, as memory loss and confusion/disorientation 
occasionally accompanied by cortical visual disturbances. In an initial stage the 
cognitive decline appears in approximately 70% of patients, and in a short time 
rises to 93%. In this subtype the patients also present ataxia, about 53% percent 
in advanced stage. Approximately 97% of patients have a spontaneous or induced 
myoclonus, and mild psychiatric symptoms as depression, anxiety and psychosis 
(Araújo 2013; Gambetti et al. 2003; Puoti et al. 2012).  
The patients with sCJD MM1 phenotype have presence of 14-3-3 protein 
and Tau in cerebrospinal fluid (CSF) and they are associated with periodic sharp 
wave complexes (PSWC) on electroencephalogram (EEG). The presence of these 
three characteristics make a positive diagnostic of sCJD MM1 (Wieser et al. 2006; 
Gambetti et al. 2003; Puoti et al. 2012). 
 
2.1.2 sCJD 129 MM2 
This subtype is very rare and account for 2 to 10% of sCJD cases, is 
observed in individuals with genotype MM2 at codon 129 of the PrP gene and 
carry type 2 of PrPSc. The mean age of disease onset is around 66 years old and 
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the duration of illness is about 14 months after onset (Bishop et al. 2010; Parchi, 
Giese, et al. 1999).  
The phenotype associated with this subtype is characterized by a cognitive 
decline in all patients and amnestic aphasia in an initial stage in 32% of patients . 
Through the course of the illness, amnestic aphasia increases to 72% of patients 
and the patients occasionally feature pyramidal sings, apraxia, Parkinsonism and 
myoclonus (Moda et al. 2012; Araújo 2013; Gambetti et al. 2003). 
Between 24 to 44% of e patients with sCJD MM2 phenotype have periodic 
sharp wave complexes (PSWC) on electroencephalogram (EEG) in the 
intermediate and advanced stages of disease. The 14-3-3 and Tau CFS test are 
positive in approximately 50% of all cases of sCJD MM2. However, the magnetic 
resonance imaging (MRI) showed abnormal imaging in most (93%) of patients 
(Puoti et al. 2012). 
 
2.1.3 sCDJ 129 VV1 
 This subtype is very rare and account between 1 to 4% of sCJD cases, it is 
the most uncommon prion disease. This subtype is observed in individuals with 
genotype VV1 at codon 129 of the PrP gene and carries type 1 of PrPSc. The 
mean age onset of disease is around 43 years old and has a long duration of 
illness, about 19 months after onset. In the initial stage it can be difficult to 
distinguish from sCJD MM2 subtype. Both subtypes have a cognitive decline and 
patients can remain mono-symptomatic for several months (Krasnianski et al. 
2006; Meissner et al. 2005). However, in patients with sCJD VV1 subtype the 
cognitive decline is slower than in patients with sCJD MM2 and is occasionally 
associated with personality changes. Through the course of the illness, all patients 
feature cognitive decline and patients occasionally feature psychiatric symptoms, 
pyramidal signs, Parkinsonism and myoclonus (Parchi, Giese, et al. 1999; 
Meissner et al. 2005).  
The patients with sCJD VV1 phenotype have presence of 14-3-3 protein 
and Tau in cerebrospinal fluid (CSF) and the electroencephalography (EEG) 
shows non-specific slowing but not periodic sharp wave (PSW) complexes. The 
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MRI is abnormal in all patients (Gambetti et al. 2003; Puoti et al. 2012; Wieser et 
al. 2006). 
 
2.2 sCDJ ataxia type 
2.2.1 sCDJ VV2 
This subtype accounts for approximately 16% of sCDJ cases and is 
observed in individuals with genotype VV at codon 129 of the PrP gene and carry 
PrPSc type 2. The mean age onset of disease is around 64 years old and the 
duration of illness is about 6 months after onset (Parchi, Giese, et al. 1999; Parchi 
et al. 2009). 
The phenotype associated with this subtype is characterized by ataxia in 
almost all patients in the initial state of disease. Through the course of the illness, 
all patients have cognitive decline and ataxia. In this subtype it is also 
characteristic myoclonus (approximately 66% of patients) and pyramidal signs 
(50% of patients) (Araújo 2013; Gambetti et al. 2003; Puoti et al. 2012).  
The patients with sCJD VV2 phenotype have presence of 14-3-3 protein and Tau 
in the CSF. The MRI is abnormal in approximately 60% of patients  (Puoti et al. 
2012). 
 
2.2.2 sCDJ MV2 
This subtype accounts for approximately 9% of sCDJ cases and is 
observed in individuals with genotype MV at codon 129 of the PrP gene and carry 
PrPSc Type 2.  The mean age onset of disease is about 64 years old and the 
duration of illness is about 17 months after onset (Parchi, Giese, et al. 1999; 
Krasnianski et al. 2006).  
 The phenotype associated with this subtype is characterized by ataxia in 
almost all patients in the initial state of disease. Cognitive decline is also common. 
Through the course of the illness, all patients have cognitive decline and ataxia. 
The patients occasionally feature Parkinsonism, myoclonus and psychiatric signs 
(Araújo 2013; Gambetti et al. 2003; Puoti et al. 2012). 
 The patients with sCJD MV2 phenotype have presence of 14-3-3 protein 
and Tau in the CSF. The MRI is abnormal in all patients (Puoti et al. 2012). 
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3 Prion disease and PrPC Cellular trafficking  
3.1 Vesicular trafficking 
Eukaryotic cells require transport of lipids and proteins between 
extracellular and intracellular environments and transport of nutrients between 
organelles also occurs. This transport is accomplished by vesicle formation which 
bud from a donor compartment and merge with an acceptor compartment in the 
secretory and endocytic pathways (Chavrier et al. 1990). Coat proteins such as 
COPI, COPII and clathrin are necessary for membrane deformation on a specific 
donor compartment. Wherein, the coat protein COPII is necessary for formation of 
buds from the endoplasmic reticulum to the golgi apparatus. The coat protein 
COPI is necessary for formation of buds from cis-golgi for retrograde transport 
back to ER and the clathrin is necessary for formation of buds from plasma 
membrane and trans-Golgi network to the late endosomes (Figure 5) (Lodish et al. 
2000b).  
 
Figure 5. General model of vesicular transport pathways: Transport between organelles is 
mediated by vesicles. Vesicle formation at various steps is driven by specific coat protein 
complexes (Take from Grant e Sato, 2006).  
 
The binding of coat proteins to the membrane is regulated by small GTP-
binding proteins called ADP-ribosylation factor (ARF) when is associated with 
COPI-coated vesicles and clathrin-coated vesicles. However, the small GTP-
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binding proteins called Sar1 are associated with COPII-coated vesicles. The small 
GTP-binding proteins bind to membrane receptors. Only and  when coat proteins 
are in the GTP-form they may lead to vesicle budding. Then the complexes of 
ARF-GTP/Sar1-GTP in the vesicle are hydrolyzed, leading to the conversion of 
ARF-GDP/Sar1-GDP form and the dissociation of coat proteins from the vesicle 
membrane (Figure 6). The non-coated vesicles are now a target for SNARES 
proteins. There are SNARES proteins that bind to non-coated vesicles called v-
SNARES, and other that bind to target membrane called t-SNARES. The v-
SNARES on the non-coated vesicle bind to the t-SNARES on the target 
membrane with the aid of Rab proteins,  leading to membrane fusion (Gahan 
2005).  
 
 
 
Figure 6. Role of ARF in the formation of COP-coated vesicles: ARF alternates between GTP-
bound and GDP-bound states. When bound to GDP, ARF associates with the membrane of trans 
Golgi network, where guanine nucleotide exchange factors (GEF) promote the exchange of the 
bound GDP for GTP. In its GTP-bound state, ARF promotes the binding of COPI coat protein 
(coatomer), leading to vesicle budding. Hydrolysis of the bound GTP then converts ARF to the 
GDP-bound state, leading to disassembly of the vesicle coat prior to fusion with the target 
membrane (Take from Gahan, 2005). 
 
3.2 Rab GTPases proteins 
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Rab GTPases belong to the largest branch of Ras superfamily of small 
GTPases that are necessary to regulate formation, transport, tethering and fusion 
of vesicles,. In Human cells were identified at least 63 different Rab family 
members and each Rab protein is localized in the membrane of a specific 
organelle (each organelle has at least one type of Rab protein) or in the cytosol 
(between 10 to 50% of Rab proteins can be detected in cytosol) (Figure 7) 
(Hutagalung & Novick 2011; Schimmoller et al. 1998; Zerial & McBride 2001). In 
cytosol Rab proteins are in an “inactive” form (GDP-bound) and a cytosolic protein 
called guanine nucleotide dissociation (GDI) bind to the Rab-GDP. Then, a 
membrane protein called GDI-displacement factor (GDF) displaces Rab from GDI 
and inserting Rab protein in the appropriate membrane. After insertion of Rab on 
the specific membrane, a protein called guanine nucleotide exchange factor (GEF) 
catalyzes the conversion of GDP-bound Rab to GTP-bound (Collins 2003). The 
Rab-GTP or “active” form is able now to interact with effector proteins located in 
that organelle and to regulate vesicle events, for instances, selecting the cargo, 
promoting vesicle movement and verifying the correct site of fusion (Pfeffer 2001). 
After, a GTPase accelerating protein (GAP) bind to the Rab-GTP form and 
catalyzes the hydrolysis of GTP-bound to GDP-bound. Thus, the GAP converts 
Rab back to its inactive form and is able now to interact with GDI that recruit Rab 
protein to the cytosol. This Rab protein can then undergo another cycle of GDP-
GTP (Figure 8). The cycle between an active and an inactive form, GTP-bound 
and GDP-bound, regulates temporal and spacial membrane transport and the 
cycle is restricted to the membrane compartments where they are localized (Zerial 
& McBride 2001). For instance, Rab5 are localized in membrane of early 
endosomes and mediatefusion of clathrin-coated vesicles to form the early 
endosome. While Rab7 proteins are localized in the membrane of late endosomes 
and mediate transport between early to late endosome. The rate of vesicles fusion 
is controlled by absolute amount of Rab-GTP form. Thus, the cycle of some 
individual Rab proteins are essential for specific vesicles fusion and their 
interaction with V-SNARE proteins are critical to define which vesicle will be fuse 
with target membrane (Figure 9) (Lodish et al. 2008; Hutagalung & Novick 2011).   
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Figure 7. The intracellular localization and associated vesicle transport pathway(s) of 
several Rab GTPases in eukaryotic cell. Rab1 regulates ER-Golgi traffic while Rab2 is involved 
in retrograde traffic from Golgi-ER. Rab6 regulates intra-Golgi traffic and several Rabs including 
Rab8, -10, and -14 regulate biosynthetic traffic from the trans-Golgi network (TGN) to the plasma 
membrane. Several Rabs are associated with endosomal traffic. Wherein, Rab5 regulated the 
formation of early endosome. Traffic can be directed towards the lysosome for degradation 
(regulated by Rab7) or to various recycling compartments to return factors to the plasma 
membrane (regulated by Rab15). Rab4 and Rab11 regulate fast and slow endocytic recycling, 
respectively. Specialized Rab functions include Rab18 controls the formation of lipid droplets. 
Rab33 together with Rab24 regulated the formation of autophagosomes. Rab21 and Rab25 
regulate transport of integrins to control cell adhesion and cytokinesis. Rab13 regulates the 
assembly of tight junctions between epithelial cells. There are several Rabs that they function is 
poorly characterized or unclear. AP, autophagosome; ERGIC, ER-Golgi intermediate compartment; 
ER, endoplasmic reticulum; EE, early endosome; LD, lipid droplet; LE, late endosome; L/V, 
lysosome/vacuole; PAS, preautophagosomal structure; RE, recycling endosome; SV, secretory 
vesicle/granule (Take from Hutagalung e Novick, 2011). 
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Figure 8. Activation cycle of small G proteins and their regulatory proteins. Rab proteins 
include COOH-terminal prenylation signals. The Rab escort protein (REP) interacts with newly 
synthesized Rab and allows the Rab geranylgeranyl transferase (RabGGT) to add two 
geranylgeranyl lipid groups to the COOH terminus of Rab. Activation of Rab is mediated by a 
Guanine nucleotide exchange factor (GEF). GTP loading induces the translocation of Rab from the 
cytosol to the plasmatic membrane and permits the interaction with effectors. To “turn off” the 
cycle, a GTPase-activating protein (GAP) accelerates the intrinsic GTPase activity of Rab, allowing 
Rab to return to its inactive state in the cytosol. A guanine nucleotide-dissociation inhibitor (GDI) 
binds specifically to GDP-bound Rab, prolonging the inactive state and sequestering the GTPase in 
the cytosol. The insertion of Rab in the target membrane is mediated by a GDI dissociation factor 
(GDF) that releases the Rab from GDI (Take from Loirand, Sauzeau e Pacaud, 2013). 
 
 
Figure 9. Hypothetical model for Rab-mediated vesicle docking. Transport vesicles carry Rabs 
in their active, GTP-bound conformations. Active Rabs recruit specific docking factors from the 
cytosol. We propose that the docking factor·Rab complex can recognize protected t-SNAREs at the 
target membrane and in some way catalyze t-SNARE deprotection. In this manner, v- and t-
SNARE pairing could take place (Take from Schimmoller, Simon e Pfeffer, 1998). 
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3.2.1 Rab7a protein  
The rab7a protein belongs to the Rab family that regulates endosomal 
traffic. This protein is localized on the surface membrane of late endosomes and 
lysosomes, thus rab7a regulates the endosomal traffic between early endosome to 
the late endosome and late endosome to the lysosome (Bucci et al. 2000; Wu et 
al. 2005). This traffic is regulated by interaction of rab7a with various effectors 
such as Vps34/p150 PI3-Kinase complex, Rab interacting lysosomal protein 
(RILP), Rabring7 and proteasome (Dong et al. 2004; Mizuno et al. 2003; Stein et 
al. 2003). The interaction between Rab7a and a specific effector regulates a 
specific step. For instance, Rab7a GTP-bound form interacts with RILP protein to 
regulate the late endosome motility on microtubules to the lysosome (Cantalupo et 
al. 2001; Jordens et al. 2001). While, the interaction of Rab7a GTP-bound with 
hVPS34 via the p150 adapter protein activate PI3P formation, together, they 
regulate internal vesicle formation within multivesicular endosomes (late 
endosome) and the transport of epidermal growth factor receptor (EGFR) into 
intraluminal vesicles of MVB (Futter et al. 2001). However, the transport of EGFR 
into intraluminal vesicles is also regulated by recruitment of alpha subunit XAPC7 
of 26S proteasome by Rab7a protein. Studies have shown that recruitment of 
XAPC7 is critical for the transport of cargo to the late endosome (such as the 
EGFR) and also its subsequent degradation (Mukherjee et al. 2005; Zafar et al. 
2011; Dong et al. 2004). 
 
3.2.2 Rab9 protein  
The rab9 proteins are localized on the surface of late endosome and trans-
Golgi network. Thus, Rab9 regulates endosomal traffic between late endosome 
and trans-Golgi network, retrograde transport. This traffic is regulated by 
interaction with several effectors such as TIP47, INPP5B, GCC185, PI3P PIKyve 
Kinase associated protein p40, NdeI, 14-3-3 protein theta and HPS4 (Hutagalung 
& Novick 2011). The interaction between Rab9 and a specific effector regulates a 
specific step. For instance, the Rab9 protein GTP-bound form interacts with TIP47 
to recycling mannose-6-phosphate (MPRs) from late endosome to the trans Golgi 
network (Lombardi et al. 1993).  
16 
 
Studies have shown the impairment of Rab9 effect on late endosomal 
trafficking to trans Golgi network (Hanna et al. 2002). 
 
4 Microtubules and Tau protein 
The cytoskeleton is one of several elements that characterize the eukaryotic 
cell and consist in a network of fibrous elements. There are three types of fibrous 
elements, microtubules (MTs), microfilaments (MFs) and neurofilaments (NFs) that 
are found in the cytoplasm (Figure 10). The microtubules are responsible for the 
shape of the cell and by transport of vesicles inside the cell. They are constituted 
by heterodimers of α- and β-tubulin that align to form a hollow tube with an outer 
diameter of 25 nm. Proteins that bind along the sides of microtubules are 
collectively called microtubule-associated proteins, or MAPs. MAPs can stabilize 
microtubules against disassembly. Tau, which is much smaller than most other 
MAPs, is present in both axons and dendrites (Lodish et al. 2000a). 
 
 
Figure 10. Microfilaments, microtubules and intermediate filaments in the nervous system. 
Each cytoskeletal structure has a distinctive ultrastructure. This schematic illustrates the major 
features of the core fibrils. The microfilament consists of two strands of actin subunits twisted 
around each other like strings of pearls. The individual subunits are asymmetrical, globular proteins 
that give the microfilament its polarity. The microtubule is also made from globular subunits, but in 
this case the basic building block is a heterodimer of α- and β-tubulins. These αβ dimers are 
organized into linear strands, or protofilaments, with β-tubulin subunits oriented toward the plus end 
of the microtubule. Protofilaments form sheets in vitro that roll up into a cylinder with 13 
protofilaments forming the wall of the microtubule. Assembly of both microfilaments and 
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microtubules is coupled to slow nucleotide hydrolysis, ATP for microfilaments and GTP for 
microtubules. The subunits of both glial filaments and neurofilaments are rod-shaped molecules 
that will self-assemble without nucleotides. The core filament structure is thought to be a ropelike 
arrangement of individual subunits. Glial filaments are typical type III intermediate filaments in that 
they form homopolymers without side arms. In contrast, neurofilaments are heteropolymers formed 
from three subunits, NFH, NFM and NFL for the high-, medium- and low-molecular-weight 
subunits. The NFH and NFM subunits have extended carboxy-terminal tails that project from the 
sides of the core filament and may be heavily phosphorylated (Take from Kirkpatrick e Brady, 
1999). 
 
Tau is a protein whose most important function is to stabilize microtubules. 
These proteins are found mostly in neuronal cells when compared to non-neuronal 
cells. They are localized along the axon and they stabilize the axonal microtubules 
and provide flexibility. The ability of Tau to cross-link microtubules into thick 
bundles may contribute to the stability of axonal microtubules (Lodish et al. 
2000a). Tau has 6 different isoforms derived from alternative splicing of a Tau 
mRNA (Kirkpatrick & Brady 1999). Three isoforms have three binding domains 
and the other three have four. The binding domains are located in the carboxyl-
terminus of the protein and are positively charged (allowing it to bind to the 
negatively charged microtubule). The isoforms with four binding domains are 
better stabilizers of microtubules than those with three binding domains. 
Phosphorylation Tau isoforms regulate the assembly and disassembly of 
microtubules. For instance, in AD Tau isolated from brain tissue is about 4 times 
more phosphorylated than in normal brains (Kopke et al. 1993; Ksiezak-Reding et 
al. 1992). 
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II. The Aims of the present study 
 The aims of the present study were undertaken to identify proteins 
interacting with PrPC that could provide new insights its physiological functions and 
pathological role. And also the role of interacting partners of PrPC, Rab7a and 
Rab9, in MM1 and VV2 subtype of CJD.  
In the present project, the Identification of interacting partners of PrPC shall 
be defined by co-localization of PrPC with Rab7a and Rab9 in neuronal cell models 
and also in cortex, cerebellum and hippocampus of mice brain wild type (WT). The 
Identification of Intracellular levels of Rab7a and Rab9 in sCJD-MM1 and sCJD-
VV2 shall be analysed in frontal cortex and cerebellum of human brain with sCJD-
MM1 and sCJD-VV2 in comparison to the control group consisting of frontal cortex 
and cerebellum of human brain without neurodegenerative diseases.  
In addition, analyse the intracellular levels of Rab7a and Rab9 in pre-
symptomatic and symptomatic stages of sCJD-MM1 shall be analysed in cortex 
and cerebellum from mice with sCJD-MM1, to investigate the intracellular levels of 
endosomal proteins during diseases progression. 
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III. Materials 
1 Antibodies  
 Antibodies used for immunoblotting (IB) and immunofluorescence (IF) are 
listed in Table 2. 
 
Table 2 List of antibodies and their application in present study 
 
Primary 
Antibody 
Origin 
 
Dilution 
IB 
Dilution 
IF 
Company/ Cat. No. 
 
Rab7(D95F2) rabbit IgG 
 
1:1000 
 
1:50 
 
Cell Signaling/9367 
Rab9(D52G8) rabbit IgG 
 
1:1000 1:50 
 
Cell Signaling/5118 
GAPDH rabbit IgG 1:1000 
 
- mAbcam 9484 
3F4 PrP mouse IgG2a 1:1000 
 
1:200 Chemicon/MAB1562 
Tau rabbit IgG 1:1000 1:50 mAbcam 64193 
 
 
 
Secondary 
antibody 
Origin 
 
Dilution 
IB 
Dilution 
IF 
Company/ Cat. 
No. 
α-mouse-Cy3 
 
goat 
 
- 1:200 
 
Dianova/115-165-
146 
α-mouse-A488 
 
 goat 
  
 
- 1:200 
 
Invitrogen/522263 
 
α-rabbit-A488 
 
goat 
 
- 1:200 
 
Molecular 
Probes/A11070 
 
 
2 Antibiotics  
 
Table 3 List of antibiotics 
 
Antibiotics Company 
Penicillin Gibco 
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Streptomycin Gibco 
3 culture media   
 
Table 4 List of culture media 
 
Culture media Company 
Agarose Biozym 
DMEM Sigma-Aldrich 
 
 
4  Chemicals  
All chemicals used in this study were obtained from Amersham (Freiburg, 
Germany), Sigma and Fluka (Deisenhofen, Germany), Merck (Haar, Germany), 
Applichem (Darmstadt, Germany), Serva (Heidelberg, Germany), Roth (Karlsruhe, 
Germany) and BioRad (München, Germany). 
 
5 Instruments and other materials  
 
Table 5 List of the instruments used in this study 
 
Appliance Model or Description 
 
Manufacture 
 
Bio-safety Cabinet 
 
Hera safe KS 
 
Heraeus/ Osterode, Germany 
 
Centrifuge 
 
5415C 
 
Eppendorf/Hamburg,Germany 
 
Centrifuge Rotina 35R 
 
Hettich/ Tuttlingen, Germany 
 
Chamber slide 
 
Lab-Tek™ II Chamber Slide, 
15453 
nunc/ New York, USA 
Culture dishes 
 
60 mm, 351016 
 
Becton Dickinson /NJ, USA 
 
Electro blotting apparatus 
 
Mini Trans-Blot® 
 
Bio-Rad /Munich, Germany 
 
Electrophoresis apparatus 
 
Mini-Protean® III 
 
Bio-Rad /Munich, Germany 
 
Electroporation cuvette 1mm, 748 011 Biozym/ Oldendorf, Germany 
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Freeze drier 
 
Alpha 1-4 LD 
 
SciQuip Ltd/ Shropshire, UK 
 
Heated magnetic stirrer 
 
iKAMAG RCT 
 
IKA-Labortechnik/ Staufen, 
Germany 
Ice machine 
 
- Ziegra /Isernhagen, Germany 
 
Incubator 
 
IFE 400 
 
Memmert/ Schwabach, 
Germany 
Microscope 
 
Zeiss LSM 510 Meta 
 
Carl Zeiss/ Goettingen, 
Germany 
Power supply 
 
Power Pac 300 
 
Bio-Rad /Munich, Germany 
 
Safe-Lock tubes  
 
0.2, 0.5, 1.5 and 2ml 
 
Eppendorf /Hamburg, 
Germany 
Semi-Dry transfer Cell 
 
Transblot SD 
 
Bio-Rad/ Munchen, Germany 
 
Serological pipettes 
 
2, 5, 10, 25ml 
 
Sarstedt /Germany 
 
plastic tubes 
 
15 and 50ml 
 
Sarstedt /Germany 
 
pH meter 
 
pH 526 
 
WTW/ Weilheim, Germany 
 
Shakers 
 
CERTOMAT R 
 
Sartorius/ Goettingen, 
Germany 
Spectrophotometers 
 
EL808 
 
Bioteck instruments/Winooski-
vermont, USA 
Sterile filter Nalgene 
 
0.2μm 
 
Sartorius/ Goettingen, 
Germany 
Sterile filter pipette tips 
 
- 
 
Biozym /Oldendorf, Germany 
 
Thermomixer 
 
5436 
 
Eppendorf/ Hamburg, 
German 
Vortexer 
 
Genie 2™ 
 
Bender and Hobein /Zurich, 
Switzerland 
Water bath 
 
1003 
 
GFL/ Burgwedel, Germany 
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6 Kits  
All the listed kits were used according to the manufacturer’s instructions.  
 
Table 6 list of the kits used in this study 
 
Name 
 
Company/ Cat. No. 
 
Application 
 
Caspase-3 activity assay kit 
 
Promega/G7220 
 
Apoptotic activity assay 
 
Lipofectamine 2000 Invitrogen Liposome-mediated 
transfection  
 
 
7 siRNA Duplex  
  
Table 7 List of siRNA Duplex  
 
siRNA Duplex 
 
Sequence (5’-3’) 
 
Accession/Cat. No. 
 
siRNA-Rab7a 
 
CUGCUGCGUUCUCCUAUUU 
 
Operon 
 
siRNA Negative control 
 
- EUROGENTES/SR-CL000-
005 
siRNA-Tau CGUACACUGAGUUCGAGCU Operon 
 
siRNA Negative control 
 
- EUROGENTES/SR-CL000-
005 
 
 
8 Software  
The list of scientific software used in the study is in table 8.  
 
Table 8 List of scientific software 
 
Program 
 
Use 
 
References 
Graphpad Prism 5 Statistical analysis GraphPad Software, Inc. 
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  California, USA 
ImageJ 1.43u 
 
Densitomatric analysis 
 
National institutes of Health, 
USA 
ImageJ 1.43u WCIF 
 
Colocalization analysis 
 
National institutes of Health, 
USA 
KC4 V3.4 
 
Absorbance reader 
 
Bioteck instruments, USA 
 
LabImage 2.7.1 
 
Densitomatric analysis 
 
Kapelan GmbH, Halle, 
Germany 
Protein-Lynx-Global-Server v 
2.1 
LS MS/MS data 
analyzer 
Micromass, Manchester, U.K 
 
Zeiss LSM 4.2.0.121 
 
Immunofluorescence 
 
MicroImaging GmbH, 
Goettingen, Germany 
 
 
9 Stock solutions 
Blocking solution for WB: 5% Milk Powder in TBS-T.  
 
Cell lysis buffer I: 50 mM Tris-HCl pH 8.0, 0.5% CHAPS, 1mM EDTA, 1% triton 
x100. 
  
Cell lysis buffer II: 7 M urea, 2 M thiourea, 4% CHAPS, 2% ampholytes, 1% DTT 
and a protease inhibitor mixture. 
  
Electrophoresis buffer (SDS-running buffer): 192 mM glycine, 0.1% SDS, 25 mM 
Tris-HCl pH 8.3. 
 
TBE: 42 mM Boric Acid, 10 mM EDTA, 50 mM Tris-HCl pH 8.0. 
 
TBS-T: TBS and 0.1% of Tween-20. 
  
TE: 0.01 M Tris-HCl, pH 7.4, 1 mM EDTA pH 8.0  
 
Transblot buffer for PVDF membrane (semi dry): 192 mM Glycine, 10% methanol, 
25 mM Tris-HCl pH 8.3.   
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IV Methods 
1 Biological samples  
1.1 Human brain 
 Frontal cortex and cerebellum samples from 30 pathologically confirmed 
sCJD patients (15 of each MM1 and VV2 subtypes) and 15 age-matched control 
cases (CON) were used in this study. All 45 samples were obtained from the 
Institute of Neuropathology Brain Bank (HUB-ICO-IDIBELL Biobank) and Biobank 
of Hospital Clinic-IDIBAPS. The mean age and gender of study cases were as 
described previously (Llorens et al. 2013). In brief, for sCJD western blot analysis 
in frontal cortex: 60 years of age in control (10M/5F), 68 sCJD MM1 (10M/5F), 63 
sCJD VV2 (5M/10F). In cerebellum, the mean age was 62 in control (11M/4F), 66 
sCJD MM1 (10M/5F) and 63 in sCJD VV2 (4M/10F). After post-mortem interval 
ranging 1h 45min. to 24h 30min., coronal sections 1cm thick were cut from one of 
the hemispheres. Along with selectively dissected areas of encephalon, coronal 
sections were rapidly frozen on metal plates over dry ice, sorted in separate bags, 
labeled with water-resistant ink and stored at -80oC until further use for 
biochemical investigations. The other hemisphere was was immersed fixed in 4% 
buffered formalin for 3 weeks for morphological studies and neuropathological 
examination and characterization. The analysis of the codon 129 genotype of PrP 
gene (Met: M or Val: V) was performed after isolation of genomic DNA from blood 
samples according to standard methods.  Western blot profile of PrPSc was 
classified as type 1 or type 2 based on electrophoretic mobility after proteinase K 
(PK) digestion. 
 
1.2 sCJD MM1 mice brain 
 Double transgenic mice overexpressing about 4-fold level of human PrPC 
with methionine at codon 129 (Met129) on a murine PrP knock-out background 
were used, as described previously (Padilla et al. 2011). Inocula were prepared 
from sCJD MM1 brain tissues as 10% (w/v) homogenates. Individually identified 6-
10 week-old mice were anaesthetised and inoculated with 2 mg of brain 
homogenate in the right parietal lobe using a 25-gauge disposable hypodermic 
needle (6 animals per group and time point). Mice were observed daily and the 
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neurological status was assessed weekly. When disease progression was evident, 
or at the end of lifespan, animals were euthanized, necropsy was performed, and 
the brain was removed. A part of the brain was fixed by immersion in 10% buffered 
formalin to quantify spongiform degeneration and perform immunohistological 
procedures. The other part was frozen at −80°C to extract protein. Survival time 
was calculated for each isolate and expressed as the mean of the survival day 
post-inoculation (DPI) of all mice scoring positive for PrPSc. Infection rate was 
determined as the proportion of mice scoring positive for PrPSc from all inoculated 
mice.  
 
2 Immunoblot 
 Tissue lysis and immunoblotting were performed as described previously 
[Zafar et al., 2014]. Briefly, cells were lysed (50mM Tris-HCl, pH8, 1% Triton X-
100, 0.5% CHAPS, 1mM DTT), and lysates were cleared of cell debris (1 min., 
1000 xg, 4°C). Cell lysates were supplemented with protease and phosphatase 
inhibitors (Roche) and were separated on 12.5% 1-DE SDS-PAGE. The proteins 
from SDS-PAGE were transferred to a PVDF blotting membrane and were 
incubated with antibodies against Rab7a and Rab9 (D95F2 and D52G8, 1:1000, 
Cell Signalling). The primary antibody was detected by incubation of secondary 
antibodies of anti-rabbit in 5% milk (1:5000). Membranes were then rinsed in 1x 
TBS-T and incubated with the corresponding horseradish peroxidase-conjugated 
secondary antibody (diluted 1:2000/1:5000) for 1h at RT. Immunoreactivity was 
detected after immersion of the membranes into enhanced chemiluminescence 
(ECL) solution and exposure to ECL-Hyperfilm (Amersham Biosciences, 
Buckinghamshire, UK). Images were documented using the ScanMaker4 
(Microtek, International), after correction for the background, and band intensities 
were determined by densitometry using Labimage (version 2.7.1, Kapelan GmbH, 
Germany) data analyzer software. 
 
3 Immunofluorescence  
 Frozen cortex, cerebellum and hippocampus of wild type mice (see section 
III, 1.2) were embedded in cryomatrix and 5 µm thick sections were sliced using 
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cryostat (Leica cryostat 3050). These sections were mounted on histological glass 
slides, fixed in acetone for 1 minute, washed with methanol for 10 minutes and air 
dried. After, slides were hydrated in PBS for 10 minutes and incubated overnight 
with primary antibodies (anti-PrPc 3F4 (1:200) and rabbit anti-Rab7a (1:50)) 
diluted in PBS supplemented with 0.2% TritonX-100 at 4ºC overnight. After 
incubated overnight, we washed 3 times for 5 min. with PBS and incubated with 
secondary antibody for 1h at room temperature. The slides were washed with PBS 
(3x, 5 min.) and mounted with cover slip using anti fade mounting medium. Slides 
were visualized using a confocal laser scanning microscope. 
 
4 Primary culture of mouse cortex 
 The wild type pregnant mice at embryonic day 14 under halothane (Sigma) 
anesthesia were sacrificed by cervical dislocation. The embryonic cerebral cortex 
were isolated and dissociated by mechanically dissociated and plated on 
polyethylenimine (1 mg/ml)-coated glass cover-slips in culture wells. For the 
brefeldin-A (BFA, Cell Signalling) treatment, cell cultures were first grown in 
Dulbecco's Modified Eagle's Medium (DMEM, Sigma-Aldrich), supplemented with 
5% fetal bovine serum (FBS, Biochrom AG), 2.5% fetal calf serum (FCS, Eurobio), 
2 mM glutamine, and 0.1% penicillin and streptomycin (Gibco), at a density of 
7x105 cell/cm2. After 3 days in vitro (DIV), the medium was replaced with N5 
medium [Kawamoto & Barrett, 1986] with 180 mg/L glucose and supplemented 
with 5% FBS and 1% FCS. Then 3 μM cytosine arabinoside (Sigma, St Louis, MO, 
USA) was added to prevent astrocyte proliferation (resulting in at least 97% pure 
neuronal culture), and 1 μM MK-801 (Research Biochemicals International) to 
present excitotoxicity (Knusel et al. 1990). The medium was changed daily. On 
DIV 5, FCS was removed and the FBS content was reduced to 1%. Cells were 
cultured at 37C in humidified 5% CO2 atmosphere. 
 
5 Liposome-mediated transient transfection  
 Transfection assay were performed using LIpofectamine 2000 (invitrogen) 
according to the manufacturer’s instructions. The primary culture of mice cortex 
(see section III, 4) were plated in 6-well plates at a cell density of 2-5 x 105 per well 
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and maintained for 24h in the medium containing 10% FBS (about 70-90% 
confluent). After cell culture reaching approximately 70% confluency, 4 µg of each 
plasmid and 10µL of Lipofectamine 2000 were incubated separately in 250 µL of 
Opti-MEM I Reduced Serum Medium (Invitrogen). After 5 min. of incubation at 
room temperature, the diluted plasmids and Lipofectamine 2000 were combined 
and incubated for an additional 20 minutes at room temperature. The DNA-
Lipofectamine 2000 complexes (5µg) were then added to each well, and the cells 
were incubated for 24h at 37°C in a CO2 incubator. After incubation, the 
transfection medium was replaced with DMEM supplemented complete medium. 
Cells were collected from confluent cultures after 48h of transfection. 
 Small interfering RNA (siRNA) transfections were performed with 100nM 
siRNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer´s instructions. Rab7a siRNA duplex was a targeted with the 
sequence 5’-CUGCUGCGUUCUCCUAUUU-3’ and Tau siRNA with the sequence 
5’-CGUACACUGAGUUCGAGCU-3’. The cells were also simultaneously 
transfected with Non-targeting siRNA duplex (control siRNA duplex negative 
control: Eurogentec) was used as a negative control. Transfected cells were 
cultured for 48h and were lysed (see section III, 6) for expression analysis and 
immunofluorescence (see section III, 3) for localization studies.  
 
6 Cell lysis 
 After transfection of primary cell culture, the cells were washed with ice cold 
1xPBS, scraped and centrifuged at 4ºC for 5 minutes at 400xg. The pallet was 
resuspended in ice cold 1x PBS and centrifuged at 4ºC for 5 min at 400xg. The 
washed cells were lysed in lysis buffer (50 mM Tris-HCL, pH 8, 1% Triton X-100, 
0.5% CHAPS, 1mM DTT, protease and phosphatase inhibitor cocktail). Cells 
lysates were homogenized with ultra sonicator on ice and the lysates were 
centrifuged for 15 min. with 543,000xg at 4ºC. Protein concentration was 
estimated by Bradford essay (see section III, 7). 
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7 Protein concentration estimated by Bradford assay 
The protein concentration was estimated by Bradford essay (Bio-Rad). 
Bradford reagent was prepared by diluting a 1x dye reagent (Bio-Rad) with dH2O 
(1:5). To standard curve, we used different dilution of BSA in ddH2O (1000µg/L; 
750µg/L; 500µg/L; 250µg/L; 100µg/L and 50µg/L) in a total volume of 20µg. 
Protein samples of unknown concentration were diluted in ddH2O (1:19). Protein 
standards (to standard curve) and protein samples of unknown concentration were 
mixed with 980µl of Bradford reagent and incubated for 10 min. at room 
temperature. The absorbance of the samples was measured at 595 nm. The 
calculation of the protein concentration was done using Microsoft Office 2007 
Excel software.     
 
8 Immunofluorescence and quantification analysis 
  Primary cells culture (see section III, 4) and primary cell culture transfected 
with siRNA (see section III, 5) were plated on chambered slides (Lab-TEK II; 
Thermo Fisher Scientific (Nunc GmbH and Co. KG), Langenselbold Site) and fixed 
for 5 min. with 100% ethanol. After, the cells were permeabilised with 0.2% Triton 
X-100 in 1xPBS for 20 minutes. Colocalization of PrPc with Rab7a and Rab9 was 
detected by applying the primary antibodies (anti-PrPc 3F4 (1:200), rabbit anti-
Rab7a (1:50) and rabbit anti-Rab9 (1:50)) for overnight at 4ºC. To Colocalization of 
Total-Tau with Rab7a was also detected by applying the primary antibodies (anti-
Tau (1:200) and rabbit anti-Rab7a (1:50)) for over-night at 4ºC. The primary 
antibodies were detected by incubation the slides for 60 min. with secondary 
antibodies (Alexa 488 conjugated anti-rabbit (1:200) and Cy3-labeled anti-mouse 
secondary antibody (1:200)). Incubation with Hoechst 33342 or with TOPRO-3 
iodide for 10 min. was performed to visualize nucleosomes. Finally, cover slips 
were placed on glass slides and mounted with Fluoromount (DAKO, Hamburg, 
Germany). After secondary antibody incubation all the steps were carried out in a 
dark humid chamber. The slides were kept dry dark at 4ºC until further microscopic 
evaluation. 
 We performed confocal laser scanning microscopy using a LSM 510 laser-
scanning microscope (Zeiss, Göttingen, Germany; 488 nm Argon, 543 and 633 nm 
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Helium-Neon excitation wavelengths) according to the manufacturer´s instructions. 
Individual images of PrPc, Rab7a, Rab9 and Tau were analyzed separately by 
ImageJ (WCIF plugin) software. For two-color analysis, stacks of images with a 
total thickness of approximately 30µm were acquired, using a dynamic range of 12 
bits per pixel. Co-localization expressed as a correlation coefficient indicates the 
strength and direction of linear relationship between two fluorescence channels. 
Pearson’s linear correlation coefficient (rp) was used in this study to calculate 
fluorescence channel correlation (Manders et al. 1992):  
 
 
 
 
 
 
Where Ri and Gi are the red and green intensity measures, respectively. 
 Raver and Gaver are the average values of Ri and Gi, respectively. 
 
The rp values can range from -1 to 1. An rp of -1 indicates a perfect negative 
linear between variables, an rp of 0 indicates no linear relationship between 
variables, an rp of >0 indicate a positive correlation and an rp of 1 indicates a 
perfect positive linear relationship between variables. The values close to zero of 
the correlation coefficient are difficult to interpret when the degree of overlap is the 
quantity to be measure. Wherein, colocalization in the context of fluorescence 
microscopy were calculated according to published methodology (Manders et al. 
1993): 
 
 
 
And 
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Where Ri,coloc = Ri if Gi > 0 and Ri,coloc = 0 if Gi = 0, and where Gi,coloc = Gi if Ri > 0 
and Gi,coloc = 0 if Ri = 0. The values of these coefficients, M1 and M2, ranges from 
0 to 1. A value of 0 indicates that none of the signal within thresholds in that 
channel exists as co-localized with the other channel. A value of 1 indicates that 
the entire signal within thresholds in that channel exists as colocalized with the 
other channel. Two perfectly colocalized images will generate a scatter plot where 
the points fall in a line at 45° to either axis. 
 
9 Statistical analysis 
The statistical significance of the difference between control and sCJD VV1 
and VV2 as also between control and siRNA in western blot was determined by 
student´s t-tests (GraphPad Prism 5 software). Pvalue less than 0.05 was 
considered statistically significant.  To statistical significance of co-localization of 
PrPc and Rab7a and Rab9 in cell culture was determined by Pearson’s correlation 
and M1 and M2 coefficients (Imagej (WCIF plugin) software.  
 
10 Ethics Statement 
 Human samples from the Institute of Neuropathology Brain Bank (HUB-
ICO-IDIBELL Biobank) and Biobank of Hospital Clinic-IDIBAPS were obtained 
following the Spanish legislation (Ley de la Investigación Biomédica 2013 and 
Real DecretoBiobancos, 2014) and the approval of the local ethics committees. 
All animal experiments were performed in accordance with the ethical 
standard set by Regierungspräsidium Tübingen (Regional Council) Experimental 
No. FLI 231/07 file reference number 35/9185.81-2. All animal experiments have 
been performed in compliance with the institutional and French national 
guidelines, in accordance with the European Community Council Directive 
86/609/EEC. The experimental protocol was approved by the INRA 
Toulouse/ENVT ethics committee. 
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IV Results 
1 Intracellular levels of Rab7a and Rab9 proteins in frontal cortex and 
cerebellum of human brain 
To know how endosomal pathway is affected in case of sCJD MM1 and 
VV2 disease, we analyzed the Rab7a and Rab9 proteins expression in frontal 
cortex of sCJDMM1 and VV2 patients and in cerebellum of sCJD MM1 and VV2 
patients by western blots. 
In frontal cortex, we observed a increased intracellular levels of Rab7a and 
a decreased intracellular levels of Rab9 in sCJD MM1 patients as compared to the 
control. However, patients with sCJD VV2 didn’t have any significance difference. 
In cerebellum, we observed an up-regulation of Rab7a and a down-regulation of 
Rab9 in sCJDMM1 and sCJDVV2 patients as compared to the control (Figure 11). 
 
 
Figure 11. Intracellular levels of Rab7a and Rab9 proteins in frontal cortex and cerebellum 
human samples of sCJD MM1 and VV2 patients: Western blots of sCJD MM1(n=15), sCJD VV2 
(n=15) and control (n=15) was performed separately. To observe the expression of Rab7a and 
Rab9 primary antibody anti-Rab7a and anti-Rab9 were used and the expression was measured by 
densitometry. (A) The Box Plot from western blot was used to represent the intracellular expression 
of Rab7 in the frontal cortex and cerebellum of sCJD MM1 and sCJD VV2 compared to the healthy 
age-matched control. sCJD MM1 and VV2 patients had a significant difference (P value < 0.01 (**) 
and P value < 0.001 (***)). (B) The Box Plot from western blot was used to represent expression of 
Rab9 protein in the cerebellum of sCJDMM1 and VV2 patients compared to the healthy age-
matched control. Both, MM1 and VV2 subtypes of sCJD had a significant difference (P value < 
0.001 (***)). 
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2 Intracellular levels of Rab7a and Rab9 in sCJD-Mice  
 To analyze the expressional regulation of Rab7a and Rab9 during disease 
progression, we performed immunoblotting in cortex and cerebellum from the mice 
with sCJD MM1 at pre-symptomatic and symptomatic stages. In the pre-
symptomatic stage, we observed low intracellular levels of Ran9 in the cortex and 
cerebellum and low intracellular levels of Rab7a in the cortex (figure 12A, B, C). 
However, we observed a high intracellular level of Rab7a in the cerebellum at pre-
symptomatic stage (figure 12B). 
 In the symptomatic stage, we observed high intracellular levels of Rab9 in 
the cortex and cerebellum and high intracellular levels of Rab7a in the cortex 
(figure 12A, B, C). In the cerebellum, we observed low intracellular levels of Rab7a 
at symptomatic stage (figure 12B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Intracellular levels of Rab7a and Rab9 in sCJD-Mice at pre-symptomatic and 
symptomatic stages: For characterization of sCJD MM1, all results of the intracellular levels of 
Rab7a and Rab9 expression from mice´s cortex and cerebellum by western blot were combined 
and divided in two different stages of disease, pre-symptomatic and symptomatic stages. (A) 
Expression of Rab7a in the cortex, (B) Expression of Rab7a in the cerebellum (C)  Expression of 
Rab9 in the cortex, (D) Expression of Rab9 in the cerebellum. 
 
 
 
A                     B 
C                     D 
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3 Co-localization of PrPc and Rab7a by Immunofluorescence 
 The significant different intracellular levels of Rab7a protein in the brain of 
sCJD patients, compared to healthy control provided evidence that Rab7a might 
be an interacting partner of PrPC. To further check the potential interaction and 
influence of Rab7a on PrPC localization and intracellular levels, we performed 
immunofluorescence of cortex, cerebellum and hippocampus sections from wild 
type mice to observe the spatial overlap between PrPC and Rab7a. Therefore, we 
used two different fluorescent labels with different emission wave length, Cy3-
labeled with anti-mouse to observe the localization of PrPC (red) and Alexa 488 
conjugate with anti-rabbit to observe the localization of Rab7a protein (green). 
Three images were taken for each sections of brain, one with fluorescent red 
(PrPC), the second with fluorescent green (Rab7a) and the third merged image 
where labeled images were combined and overlapping pixels turn yellow. PrPC 
showed co-localization with Rab7a in the cytosolic area of cortex, cerebellum and 
hippocampus. In hippocampus and cortex the co-localization were disperse and in 
cerebellum it was in a specific region. To determine how much green and red 
colours overlap, Imagej (WCIF plugin) software was used. Therefore, after 
merging of PrPc with Rab7a images, the software generates a scatter plot. A 
scatter plot is a diagram with green intensities in the X axes and red intensities in 
the y axes. In the situation of co-localization, the points fall in a line at 45° either 
axis with yellow intensities. The colour of scatter plot pixel represents the colour of 
merged image. The scatter plot didn´t show the frequency of the pixels, but is used 
to show a partial co-localization between PrPc and Rab7a (Figure 13A).  
To quantify co-localization of PrPC and Rab7a, we used Pearson’s 
correlation coefficient and M1 and M2 coefficients. The values for Pearson’s will 
range from 1 to -1, where values of 1 indicate perfect correlation, 0 indicate 
random localization and -1 indicate perfect exclusion. Values close to zero and 
negative for Pearson’s correlation coefficient for fluorescent images can be difficult 
to interpret. However, a value close to 1 does indicate reliable co-localization. The 
values of M1 and M2 range from 0 to 1, where values of 0 indicate that none of 
signal within thresholds in that channel colocalizes with the other channel. A value 
of 1 indicates that the entire signal within thresholds in that channel co-localizes 
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with the other channel. The Pearson´s correlation and M1 and M2 were used to 
characterize the degree of overlap between images. 
 
 
Figure 13. Co-localization of PrPc and Rab7a: (A) PrPC and Rab7a proteins were analyzed by 
using 3F4 anti-PrPC (red), anti-Rab7a (green). (B) Statistical analysis (student´s T-test) shown a 
significant co-localization of PrPC and Rab7a in the cortex, cerebellum and hippocampus (Pvalue 
<0,01 (**)) when compared to the cortex. 
 
4 Intracellular levels of PrPc and Rab7a/Rab9 protein in primary culture of 
mouse cortex 
To further check the potential interaction and influence of Rab7a and Rab9 
on PrPC localization and intracellular levels, we performed the 
immunofluorescence in primary cells culture of mice´s cortex from wild type mice 
to observe the spatial overlap between PrPc and Rab7a/Rab9. To analyze the co-
localization between PrPc and Rab7a/Rab9, we performed two slides with two 
different fluorescent labels with different emission wavelength. In one of the slides, 
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we used Cy3-labeled with anti-mouse to observe the localization of PrPc (red) and 
Alexa 488 conjugate with anti-rabbit to observe the localization of Rab7a protein 
(green). In the other slide, we used Cy3-labeled with anti-mouse to observe the 
localization of PrPc (red) and Alexa 488 conjugate with anti-mouse to observe the 
localization of Rab9 protein (green) (figure 14A). Three images were taken from 
each slides; one with fluorescent red (PrPc), the second with fluorescent green 
(Rab7a or Rab9) and the third merged image where the labeled was combined 
and overlapping pixels turn yellow. PrPc showed co-localization with Rab7a and 
Rab9 in the cytosolic area, however the percentage of co-localization of PrPc with 
Rab7a was most significant than PrPc with Rab9 (figure 14B). The scatter plot 
didn´t show the frequency of the pixels, but is used to show a partial co-
localization between PrPc and Rab7a or Rab9 (Figure 14A). The results of 
Pearson’s correlation coefficient of co-localization demonstrated a partial co-
localization between Rab7a and PrPC (Figure 14). 
 
 
Figure 14. Co-localization of PrPc with Rab7a/Rab9 in primary culture of mouse cortex: (A) 
PrPC, Rab7a and Rab9 protein was analyzed by using 3F4 anti-PrPC (red), anti-Rab7a (green) 
antibodies and anti-Rab9 (green). (B) Percentage of co-localization of PrPC and Rab7a, and 
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A 
B      C   
                  
percentage of co-localization PrPC and Rab9. The student´s T-test showed less co-localization of 
PrPC and Rab9 when compared between PrPC and Rab7a protein (Pvalue < 0,01 (**)). 
 
PrPC distribution was then evaluated after depleting Rab7a expression 
using the siRNA duplex. The localization pattern of PrPC staining was dramatically 
altered in primary culture cells treated with siRNA-Rab7a when compared to the 
primary cells treated similarity but without siRNA (control) (Figure 14A and 15A). 
We also observed a increased intracellular levels of PrPC (Figure 15B). However, it 
was not observed any significant difference in the intracellular levels of Rab9 
primary culture cells treated with siRNA-Rab7a (Figure 15C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Effect of Rab7a depletion on PrPC localization: (A) Primary culture cortex mice was 
treated with siRNA duplex (100 nM) to target Rab7a. Forty-eight hours after transfection, PrPC, 
Rab7a and Rab9 intracellular levels was analyzed by using 3F4 anti-PrPC (red), anti-Rab7a (green) 
and anti-Rab9 (green) antibodies. The PrPC is clustered in specific regions of the cytoplasm after 
treated with siRNA-Rab7a. (B, C) Statistical analysis (student´s T-test) show a significant decresed 
intracellular levels of PrPC (Pvalue <0,001 (***)) when compared to the control and the intracellular 
levels of Rab9 did not have any significant difference. 
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5 siRNA downregulation of Rab7a/Rab9 and Tau  
 To know if Tau protein affects the intracellular levels of Rab7a and 
Rab9 proteins, we analyzed the intracellular levels of Rab7a and Rab9 from a cell 
culture of wild type mice´s cortex treated with siRNA-Tau and without siRNA 
treated (control) by western blot. After treatment with siRNA-Tau, the expression 
of Tau protein was inhibited. We observed a significant increased intracellular 
levels of Rab7a and Rab9 proteins in cell culture treated with siRNA-Tau as 
compared with control (Figure 16B). 
 
 
Figure 16. Western blot of primary cortical neurons: (A) Cell culture of wild type mice´s cortex 
was transfected with siRNA duplex (100nM) to the target Tau. The intracellular levels of Rab7a and 
Rab9 was analyzed after 48 H of transfection by immunoblotting using specific Rab7a and Rab9 
antibodies. (B) Densitometry analysis from four independent immunoblotting experiments and 
significance was calculated by student´s T-test (Pvalue < 0.05 (*), < 0.01 (**), < 0.001 (***)). 
 
6 Tau and Rab7a  
Western blot essay in cell cultures with siRNA-Tau provided evidence that 
Tau might be an interacting partner of Rab7a (figure 16B). To further check the 
potential interaction and influence of Tau on Rab7a localization and intracellular 
levels, cell cultures of mice´s cortex from wild type mice were treated with siRNA-
Tau, siRNA-Rab7a and Nt-siRNA (control) followed by immunofluorescence. To 
analyze the co-localization between Tau and Rab7a, we performed three slides 
with two different fluorescent labels and different emission wavelengths. In each 
slide we used Cy3-labeled with anti-mouse to observe the localization of Total-Tau 
(red) and Alexa 488 conjugate with anti-rabbit to observe the localization of Rab7a 
protein (green) (figure 17A). Three images were taken from each slide; one with 
  A   B 
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fluorescent red (Total-Tau), the second with fluorescent green (Rab7a) and the 
third merged image where the labeled images were combined and overlapping 
pixels turn yellow. Total-Tau showed a co-localization with Rab7a in cytosolic area 
in cell cultures without siRNA (control) (figure 17C). In cell cultures treated with 
siRNA-Rab7a, we observed a significant decreased intracellular levels of Total-
Tau and their localization was altered as compared with control (figure 17A).  
In cell cultures treated with siRNA-Tau, we observed a significant increased 
intracellular levels of Rab7a and localization of Rab7a was altered as compared to 
cell cultures without siRNA (control) (figure 17A).  
 To determine the percentage of overlap, we used Imagej (WCIF plugin) 
software. To quantify the co-localization of Total-Tau with Rab7a, we used 
Pearson’s correlation and M1/M2 coefficient. 
 
 
 
 
 
 
A 
B     C      
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Figure 17. Intracellular levels of Total-Tau and Rab7a in a cortex primary culture of wild type 
mice treated with siRNA-Rab7a and siRNA-Tau: (A) Primary cultures of mice´s cortex was 
treated with siRNA duplex (100 nM) to target Rab7a and Tau and without siRNA (control). Forty-
eight hours after transfection, Total-Tau and Rab7a expression was analyzed by using anti-Tau 
(red) and anti-Rab7a (green) antibodies. The Total-Tau is clustered in specific regions of the 
cytoplasm after treated with siRNA-Rab7a. (B) Statistical analysis (student´s T-test) shown a 
significant decreased intracellular levels of Total-Tau in cell culture treated with siRNA-Rab7a and 
an increased intracellular expression of Rab7a in cell culture treated with siRNA-Tau when 
compared with cell culture without siRNA. (C) Student´s T-test shown a decrease of co-localization 
of Rab7a and Total-Tau in cell cultures treated with siRNA-Rab7a, siRNA-Tau and Nt-siRNA 
(Pvalue < 0.05 (*), < 0.01 (**), < 0.001 (***)). 
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V. Discussion 
Postmortem cortex and cerebellum´s samples from sCJD-MM1 and sCJD-
VV2 patients were examined; we identified significant decreased intracellular 
levels of endosomal protein Rab9 and an increased intracellular levels of 
endosomal protein Rab7a in the cortex and cerebellum of human samples from 
sCJD-MM1 and an increased intracellular levels of Rab7a in the cerebellum of 
human samples from sCJD-VV2. The increased intracellular levels of Rab7a 
indicating that specific endosomal network proteins are overexpressed in the 
specific regions of sCJD-MM1 and sCJD-VV2 patients.  
 In vivo studies with sCJD of mice showed two stages of the disease, pre-
symptomatic and symptomatic, while in humans the only possible stage is 
symptomatic stage. The increased intracellular levels of  Rab7a in the 
symptomatic and also in pre-symptomatic stage in the brain of mice, suggesting 
that endosomal protein Rab7a could potentially be used as a sCJD-MM1 and 
sCJD-VV2 diagnostic biomarker before symptomatic stage settles. In case of 
sCJD, the presence of Rab7a protein together with other characteristics will allow 
to make a positive diagnostic. However, studies are required to know if the 
intracellular levels of Rab7a protein are high in symptoms of the disease in 
humans.  
 
1 PrPC and Rab7a/Rab9   
 Rab7a and Rab9 are located in specific intracellular compartments, late 
endosome, however the Rab7a protein is also located in lysosomes. Rab7a is the 
only Rab GTPases protein that is found in lysosome (Hutagalung & Novick 2011). 
Rab7a regulates membrane traffic from the early endosome to the late endosome 
and from late endosome to the lysosome for degradation. It is responsible for 
continuous fusion event between late endosome and lysosomes (Bucci et al. 
2000). While, Rab9 protein is involved in the regulation of   membrane trafficking 
between the late endosome and trans-Golgi network for recycling (Lombardi et al. 
1993).  
The cortical neural cell lines from wild type mice showed a significant co-
localization between Rab7a and PrPC than Rab9 and PrPC. When we transfected 
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this cells line with siRNA-Rab7a the accumulation of PrPC increased in cytosolic 
region and their localization was also modified to a punctuated form when 
compared with control cells. In contrast, the intracellular levels of Rab9 showed no 
significant regulation in this cell line transfected with siRNA-Rab7a. This data 
suggests that a great amount of internalized PrPC by endocytosis in normal cells is 
a target to the degradation pathway and when occurs Rab7a depletion it results in 
an impairment of PrPC trafficking between early endosome and the late endosome 
and between late endosome and the lysosome, leading to accumulation of PrPC in 
the endocytosis pathway. However, the intracellular levels of PrPC is significantly 
less in cells with Rab7a depletion than in normal cells. This could suggest that 
PrPC traffic can be made by other endocytosis pathway, for instance, exocytosis 
when the Rab7a is compromised.  
In case of prion disease, the conversion of PrPC to the PrPSc occurs in the 
plasma membrane or along the endocytic pathway, before PrPSc is exposed to 
endosomal and lysosomal proteases (Caughey et al. 1991). Studies have reported 
that the majority of PrPSc is intracellular (Taraboulos et al. 1990), and primarily 
sequestered with in lysosomes ( Godsave et al., 2008; Borchelt, Taraboulos e 
Prusiner, 1992; Caughey et al., 1991; Marijanovic et al., 2009; McKinley et al., 
1991), with little localization at the cell surface (Vey et al. 1996). In our study, we 
found increased intracellular levels of Rab7a in sCJD MM1 patients, which could 
suggest an overload of endosomal traffic for degradation. The higher amount of 
internalized PrPC is a normal target for endocytic pathway and their conversion to 
PrPSc, occuring at plasma membrane level or along an endocytic pathway, could 
suggest that increased intracellular levels of Rab7a is contributing  to an 
accumulation of PrPSc in lysosomes under the pathophysiological conditions in 
prion diseases.  
 
2 Total-Tau and Rab7a 
 Tau proteins belong to the family of microtubule-associated proteins and 
they provide flexibility and stability to microtubules. Microtubules are responsible 
for the shape of the cell and serve as tracks for axonal transport (Lodish et al. 
2008). Dysfunctions of Tau proteins could possibly lead to increased 
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phosphorylation and decreased binding to microtubules, ultimately leading to 
disruption of microtubules (Dixit et al. 2008). Disruption of microtubules changes 
vesicular biogenesis, vesicle/organelle trafficking, synaptic signaling and it is one 
of the several neurodegenerative disorders in patients with neurodegenerative 
diseases (Fletcher & Mullins 2010). Cells lines treated with siRNA-Tau showed 
significantly increases intracellular levels of Rab7a and Rab9 and alteration of 
Rab7a localization when Tau is depleted lead to increase dendritic spines.   
Neural cortex cell lines from wild type mice showed a significant co-
localization between Rab7a and Tau. When we transfected this cells lines with 
siRNA-rab7a the accumulation of Tau decreases in cytosolic region and their 
localization was also modified when compared with control cells. These findings 
suggest that Tau might be degraded after Rab7a depletion.  
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VI Conclusion 
The sCJD MM1, sCJD VV2 and Alzheimer's disease are the most 
common form of prion disease and neurodegenerative dementia, 
respectively (Selkoe 1999; Gambetti et al. 2003). Due of the high rate of 
individuals affected with these diseases worldwide, it is important to 
develop new knowledge about their pathological features in order to 
diagnose them in early stage of the disease and develop new treatments 
before irreversible brain damage occurs. As the fast progressive 
neurodegeneration (CJD) and slow progressive classical AD are 
characterized by deposits of aggregated proteins, this accumulation of 
proteins may activates the protein quality control mechanisms, i.e in the 
endoplasmic reticulum, the unfolded protein response (UPR). Rab7a which 
is involved in the retrograde Golgi-ER trafficking and may function as a 
post-ER quality control system (Hutagalung & Novick 2011), in our study 
shows an increased intracellular levels of Rab7a in sCJD MM1 and VV2 
cases. Thus, our study demonstrate the possible common interactive 
association of fast progressive and slow progressive neurodegenerative 
pathway, which the endosomal pathway is more active during fast 
progressive sCJD MM1, sCJD VV2 than in AD. In conclusion, this study 
may help to characterize the fast progressive and slow progressive disease, 
CJD and AD cases. Furthermore, it could be a step forward for the 
discovery of new biomarkers that could help diagnose the diseases of sCJD 
and AD before postmortem and also it could be a step ahead to 
development of new treatment strategies for diseases subtype specific 
manner. 
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